Alnylam Pharma (ALNY) Tops Q4 EPS by 49c; offers guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $266.11 +0.61%
Revenue Growth %: +15.3%
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.3%
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($0.77), $0.49 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $346.29 million versus the consensus estimate of $436.08 million.
GUIDANCE:
Alnylam Pharma sees FY2024 revenue of $1400-1500 million, versus the consensus of $1770 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
